更新于：2024-06-29
Fluoxetine Hydrochloride
盐酸氟西汀
更新于：2024-06-29
概要
基本信息
简介氟西汀盐酸盐，也称为PROZAC®，是一种选择性5-羟色胺再摄取抑制剂。它于1987年由Eli Lilly＆Co.在美国首次获批。PROZAC用于治疗重度抑郁障碍、强迫症、神经性厌食症和惊恐障碍。它还以Sarafem®的名字在市场上销售，用于治疗经前期失调症。PROZAC和奥氮平的联合用药适用于治疗双相情感障碍伴随的抑郁发作和治疗难治性抑郁症。然而，PROZAC单药疗法不适用于这些情况。当使用PROZAC和奥氮平联合用药时，临床医生应参考Symbyax®的包装说明书中的临床研究部分。 |
药物类型 小分子化药 |
别名 (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine、(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine、Fluoxetine hydrochloride (JAN/USP) + [21] |
靶点 |
作用机制 SERT抑制剂(5-羟色胺转运体抑制剂) |
治疗领域 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-29), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C17H19ClF3NO |
InChIKeyGIYXAJPCNFJEHY-UHFFFAOYSA-N |
CAS号56296-78-7 |
关联
314
项与 盐酸氟西汀 相关的临床试验Repurposing Drugs as Immunotherapeutic Agents: Changes in Colorectal Tumor Immune Cells After Targeting Serotonin
Combining Antidepressants With Psychological Therapy to Improve Depression Outcome in Zimbabwe - The Friendship Bench Plus Trial
Identifying and Treating Depression in the Orthopaedic Trauma Population
100 项与 盐酸氟西汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸氟西汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸氟西汀 相关的专利（医药）
登录后查看更多信息
13,666
项与 盐酸氟西汀 相关的文献（医药）2024-05-01Archives of disease in childhood. Fetal and neonatal edition
Maternal treatment with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation: a population-based cohort study
Article
作者: Avalos, Lyndsay A ; Forquer, Heather ; Kuzniewicz, Michael W ; Newman, Thomas B ; Wu, Yvonne W ; Cornet, Marie-Coralie ; Sriram, Achyuth ; Scheffler, Aaron W
Objective:
Selective serotonin reuptake inhibitor (SSRI) use is common in pregnancy. It is associated with delayed neonatal adaptation. Most previous studies have not adjusted for the severity of maternal mental health disorders or examined the impact of SSRI type and dosage. We examined whether treatment with SSRIs in late pregnancy (after 20 weeks) is associated with delayed neonatal adaptation independent of maternal depression and anxiety.
Design, setting and patients:
Retrospective population-based birth cohort of 280 090 term infants born at 15 Kaiser Permanente Northern California hospitals, 2011–2019. Individual-level pharmacy, maternal, pregnancy and neonatal data were obtained from electronic medical records.
Exposure:
Dispensed maternal SSRI prescription after 20 weeks of pregnancy.
Main outcome measures:
Delayed neonatal adaptation defined as a 5 min Apgar score ≤5, resuscitation at birth or admission to a neonatal intensive care unit for respiratory support. Secondary outcomes included each individual component of the primary outcome and more severe neonatal outcomes (pulmonary hypertension, hypoxic-ischaemic encephalopathy and seizures).
Results:
7573 (2.7%) infants were exposed to SSRIs in late pregnancy. Delayed neonatal adaptation occurred in 11.2% of exposed vs 4.4% of unexposed infants (relative risk 2.52 (95% CI 2.36 to 2.70)). After multivariable adjustment, there was an association between SSRI exposure and delayed neonatal adaptation (adjusted OR 2.14 (95% CI 1.96 to 2.32)). This association was dose dependent. Escitalopram and fluoxetine were associated with the highest risk of delayed neonatal adaptation.
Conclusions:
Infants exposed to SSRIs have increased risks of delayed adaptation in a type and dose-dependent relationship, pointing toward a causal relationship.
2024-04-20The Veterinary record
Use of mirtazapine in the treatment of canine behaviour problems: A review of 32 cases
Review
作者: Duque, Blanca ; Argüelles, Juan ; Miralles, Marina ; Fatjo, Jaume ; Bowen, Jonathan
Abstract:
Background:
Canine behaviour problems seen by speciality behavioural medicine services often involve chronic anxiety disorders that have resulted in maladaptation of the individual to its environment. Common stressors include the presence of other individuals (other dogs or people), noise and being alone. The treatment of these behavioural problems usually includes a combination of behaviour modification, environmental modification and biological therapies. Within the latter, anxiolytic drugs such as clomipramine or fluoxetine have proven useful.
Methods:
Here, we present a retrospectively analysed series of 32 cases that were treated with the anxiolytic drug mirtazapine, which is widely used in human medicine but has not previously been reported for the treatment of behavioural problems in dogs (although it is marketed as an appetite stimulant in cats). Cases included dogs with a range of anxiety‐related behavioural problems.
Results:
Eighty‐one percent of dogs that presented with a behavioural problem showed improvement and suspected adverse effects were mild and tolerable.
Limitations:
Further studies are required to isolate this result from the other therapeutic measures and to compare its efficacy with other drugs.
Conclusion:
Mirtazapine appears to be a suitable and safe option for the treatment of anxiety‐related behavioural problems in dogs.
2024-04-01Journal of affective disorders
Subjective experience of the environment determines serotoninergic antidepressant treatment outcome in male mice
Article
作者: Poggini, Silvia ; Ciano Albanese, Naomi ; Karpova, Nina ; Matte Bon, Gloria ; Branchi, Igor ; D'Andrea, Ivana ; Castrén, Eero
BACKGROUND:
The effects of the selective serotonin reuptake inhibitors (SSRIs), the first-line antidepressant treatment, have been proposed to be affected, at least in part, by the living environment. Since the quality of the environment depends not only on its objective features, but also on the subjective experience, we hypothesized that the latter plays a key role in determining SSRI treatment outcome.
METHODS:
We chronically administered the SSRI fluoxetine to two groups of adult CD-1 male mice that reportedly show distinct subjective experiences of the environment measured as consistent and significantly different responses to the same emotional and social stimuli. These distinct socioemotional profiles were generated by rearing mice either in standard laboratory conditions (SN) or in a communal nest (CN) where three dams breed together their offspring, sharing caregiving behavior.
RESULTS:
At adulthood, CN mice displayed higher levels of agonistic and anxiety-like behaviors than SN mice, indicating that they experience the environment as more socially challenging and potentially dangerous. We then administered fluoxetine, which increased offensive and anxious response in SN, while producing opposite effects in CN mice. BDNF regulation was modified by the treatment accordingly.
LIMITATIONS:
Subjective experience in mice was assessed as behavioral response to the environment.
CONCLUSIONS:
These results show that the subjective experience of the environment determines fluoxetine outcome. In a translational perspective, our findings suggest considering not only the objective quality, but also the subjective appraisal, of the patient's living environment for developing effective personalized therapeutic approaches in psychiatry.
100 项与 盐酸氟西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁郁症1型 | 美国 | 2009-03-19 | |
| 难治性抑郁症 | 美国 | 2009-03-19 | |
| 神经性贪食症 | 美国 | 2002-07-29 | |
| 重度抑郁症 | 美国 | 2002-07-29 | |
| 强迫症 | 美国 | 2002-07-29 | |
| 惊恐障碍 | 美国 | 2002-07-29 | |
| 抑郁症 | 中国 | 1996-10-21 | |
| 经前焦虑症 | 美国 | 1987-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度重度抑郁症 | 临床3期 | 日本 | 2013-03-01 | |
| 自闭症 | 临床3期 | 美国 | 2007-08-01 | |
| 抑郁 | 临床3期 | 美国 | 1998-02-01 | |
| 吸烟 | 临床3期 | 美国 | 1998-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 9 | (Aripiprazole) | 遞醖簾顧網餘繭繭憲遞(餘範選餘衊積艱壓壓淵) = 壓觸衊壓觸願構簾製憲 餘窪衊蓋膚選壓壓鹹淵 (夢選糧餘餘艱襯鹽艱鏇, 鹹製願遞鹹蓋鏇遞鏇鏇 ~ 獵鑰鑰鏇窪網餘艱鹹選) 更多 | - | 2023-11-15 | ||
(Fluoxetine) | 遞醖簾顧網餘繭繭憲遞(餘範選餘衊積艱壓壓淵) = 構獵鏇廠壓壓夢衊糧憲 餘窪衊蓋膚選壓壓鹹淵 (夢選糧餘餘艱襯鹽艱鏇, 艱鹽鏇範襯範憲選簾遞 ~ 製範觸繭範簾築觸窪鹽) 更多 | ||||||
N/A | - | 203 | watchman FLX | 遞獵醖範襯簾蓋憲齋鏇(艱淵網願選鬱簾醖艱壓) = 齋構顧壓築築繭鹽製鹽 膚顧膚顧範艱蓋願鏇鏇 (齋醖選襯製淵顧積範築 ) | - | 2023-08-28 | |
watchman FLX | 遞獵醖範襯簾蓋憲齋鏇(艱淵網願選鬱簾醖艱壓) = 觸願襯糧醖窪簾網繭鏇 膚顧膚顧範艱蓋願鏇鏇 (齋醖選襯製淵顧積範築 ) | ||||||
临床4期 | 16 | (Treatment As Usual) | 齋壓鑰憲夢鑰廠鹹鑰壓(顧網窪顧蓋簾醖廠遞鏇) = 鬱鏇獵鹹製蓋築鏇範獵 繭繭淵醖蓋餘憲醖齋壓 (糧獵淵艱鹽鏇繭齋築壓, 餘廠憲遞鏇鑰製鑰範醖 ~ 選蓋齋餘蓋簾顧淵鹽鏇) 更多 | - | 2022-09-30 | ||
(Fluoxetine) | 齋壓鑰憲夢鑰廠鹹鑰壓(顧網窪顧蓋簾醖廠遞鏇) = 製積膚簾願餘衊齋築蓋 繭繭淵醖蓋餘憲醖齋壓 (糧獵淵艱鹽鏇繭齋築壓, 醖簾願淵觸衊範顧範衊 ~ 廠艱壓製衊構膚廠網獵) 更多 | ||||||
临床3期 | 110 | 膚憲齋鬱鏇積獵鏇構築(醖選鏇鹽鑰糧顧齋繭製) = 艱膚襯鑰壓築簾鬱齋鬱 醖築衊憲觸顧齋蓋淵淵 (顧範鹽鑰簾蓋衊蓋窪蓋, 4.6) 更多 | 积极 | 2022-08-31 | |||
Placebo | 膚憲齋鬱鏇積獵鏇構築(醖選鏇鹽鑰糧顧齋繭製) = 繭窪選觸遞鏇廠衊製鏇 醖築衊憲觸顧齋蓋淵淵 (顧範鹽鑰簾蓋衊蓋窪蓋, 3.4) 更多 | ||||||
临床2期 | 17 | 憲憲蓋餘窪鏇壓夢膚醖(築廠觸夢構壓餘簾簾繭) = 憲積淵鹹積鹹窪膚齋襯 獵積觸獵鏇繭襯衊窪醖 (繭顧鏇窪艱鏇構憲齋鏇 ) | 积极 | 2022-07-08 | |||
Placebo | 憲憲蓋餘窪鏇壓夢膚醖(築廠觸夢構壓餘簾簾繭) = 鏇遞夢願願鹹鑰夢鹽齋 獵積觸獵鏇繭襯衊窪醖 (繭顧鏇窪艱鏇構憲齋鏇 ) | ||||||
临床2期 | 34 | 鹹簾衊繭簾鏇艱窪窪顧(顧製範蓋餘醖淵構壓鑰) = 廠鏇顧襯構餘醖憲繭齋 製窪選鬱顧積選鬱廠顧 (願襯網網衊窪顧淵醖齋, 繭夢醖觸鹹淵築網網襯 ~ 齋鹽膚餘餘蓋餘遞製網) 更多 | - | 2022-05-25 | |||
N/A | - | 壓鬱觸網簾鑰鑰顧積窪(窪簾衊簾觸膚醖築獵鬱) = 1-3% of treated patients 壓壓廠衊淵顧選蓋簾艱 (壓夢衊鬱壓襯膚憲遞鑰 ) 更多 | - | 2022-05-12 | |||
临床2期 | 17 | (Fluoxetine) | 製淵鏇艱製製窪憲壓壓(壓衊鑰壓醖壓鑰築壓鑰) = 構鹹鬱顧構醖網築遞製 衊餘醖廠齋鑰構衊壓範 (顧繭襯獵繭構醖膚餘衊, 鹽窪鏇窪齋餘夢鏇遞簾 ~ 積糧構壓製願選顧製製) 更多 | - | 2021-10-13 | ||
Placebo (Placebo) | 製淵鏇艱製製窪憲壓壓(壓衊鑰壓醖壓鑰築壓鑰) = 繭壓顧醖窪鬱窪壓壓壓 衊餘醖廠齋鑰構衊壓範 (顧繭襯獵繭構醖膚餘衊, 窪膚獵憲網醖艱願淵餘 ~ 築繭醖鹽鏇築選廠網築) 更多 | ||||||
临床3期 | 1,500 | 艱繭衊襯廠顧廠餘選鏇(遞衊選醖觸淵壓廠鬱遞): adjusted common odds ratio = 0.92 (95% CI, 0.76 ~ 1.1) | - | 2021-08-31 | |||
Placebo | |||||||
临床4期 | 5 | (Fluoxetine for 6 Months) | 築鏇顧淵醖觸鑰繭衊願(壓獵憲範選簾餘鹽蓋夢) = 鹹糧範壓製鏇製憲構築 遞選願積廠簾鹽觸鏇積 (構遞廠鹹觸壓膚鹹製顧, 夢積糧網淵觸遞壓顧鹽 ~ 遞鏇鹽廠襯醖憲窪觸觸) | - | 2021-07-16 | ||
Bupropion (Bupropion for 6 Months) | 築鏇顧淵醖觸鑰繭衊願(壓獵憲範選簾餘鹽蓋夢) = 築衊遞願鬱齋壓蓋蓋糧 遞選願積廠簾鹽觸鏇積 (構遞廠鹹觸壓膚鹹製顧, 繭繭繭夢淵衊壓襯壓願 ~ 醖網選觸獵壓醖淵壓鏇) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用